PSNL Personalis, Inc.

Nasdaq personalis.com


$ 8.52 $ 0.31 (3.77 %)    

Wednesday, 15-Oct-2025 17:08:44 EDT
QQQ $ 602.27 $ 4.22 (0.71 %)
DIA $ 462.77 $ 0.00 (0 %)
SPY $ 665.14 $ 2.94 (0.44 %)
TLT $ 90.72 $ -0.20 (-0.22 %)
GLD $ 387.63 $ 6.60 (1.73 %)
$ 8.53
$ 8.46
$ 8.22 x 5
$ 8.79 x 100
$ 8.31 - $ 8.95
$ 2.83 - $ 8.95
1,128,074
na
756.42M
$ 1.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-personalis-maintains-85-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...

 personalis-announces-new-data-from-astrazeneca-phase-3-clinical-trial-in-lung-cancer-showing-personalis-mrd-test-next-personal-is-strong-predictor-of-outcomes-in-patients-with-stage-ii-iiib-egfr-mutated-nsclc-receiving-neoadjuvant-therapy

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

 hc-wainwright--co-maintains-buy-on-personalis-lowers-price-target-to-85

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...

 personalis-lowers-fy2025-sales-guidance-from-80000m-90000m-to-70000m-80000m-vs-83326m-est

Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $80.000 million-$90.000 million to $70.000 million-$80.000 million vs...

 personalis-sees-q3-sales-12000m-14000m-vs-18874m-est

Personalis (NASDAQ:PSNL) sees Q3 sales of $12.000 million-$14.000 million vs $18.874 million analyst estimate.

 personalis-q2-eps-023-beats-024-estimate-sales-17203m-miss-20114m-estimate

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by...

 cramer-says-tesla-dominates-while-ouster-is-too-speculative

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternat...

Core News & Articles

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer typesPersonalis, Inc. (NASDA...

 personalis-presents-new-results-from-calla-phase-3-study-showing-for-first-time-ultrasensitive-next-personal-ctdna-blood-test-detected-cervical-cancer-progression-up-to-16-months-ahead-of-imaging

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results...

 personalis-presents-new-clinical-results-from-predict-dna-and-scandare-studies-highlighting-capabilities-of-ultrasensitive-next-personal-ctdna-blood-test-for-monitoring-and-predicting-nat-response-in-tnbc

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinica...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION